2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
Status:
Terminated
Trial end date:
2019-07-10
Target enrollment:
Participant gender:
Summary
This phase 2 clinical trial will evaluate the efficacy of the combination of pemetrexed and
sorafenib in patients with recurrent or metastatic Triple Negative Breast Cancer (TNBC).
Candidate pharmacodynamic and predictive biomarkers will also be evaluated.